Xenetic Biosciences, Inc.
Business
Xenetic Biosciences is a biopharmaceutical company developing immuno-oncology treatments, primarily focused on advancing proprietary DNase technology designed to target neutrophil extracellular traps to improve outcomes of existing cancer therapies. The company is pursuing systemic DNase for pancreatic cancer, colorectal carcinoma and other solid tumors, alongside preclinical programs in DNase-armored CAR T cells and legacy programs in protein drug delivery (PolyXen) and erythropoietin variants. Xenetic operates through research collaborations with Scripps Research, University of Virginia, PeriNess and contract manufacturers, with active exploratory clinical studies underway in Israel.
Summary from 10-K filed 2026-03-12
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Royalty revenue | 3 | 3 | 3 | 2 | 1 | |
| Total revenue | 3 | 3 | 3 | 2 | 1 | |
| Research and development | −3 | −3 | −3 | −5 | −3 | |
| General and administrative | −3 | −3 | −4 | −4 | −4 | |
| Total operating costs and expenses | −6 | −7 | −7 | −8 | −7 | |
| Loss from operations | −3 | −4 | −5 | −7 | −6 | |
| Other income (expense) | 5,725 | −5,708 | 25,380 | −1,597 | 1,119 | |
| Interest income, net | 147,997 | 249,861 | 355,757 | 167,152 | 100,467 | |
| Total other income, net | 153,722 | 244,153 | 381,137 | 165,555 | 101,586 | |
| Net loss | −3 | −4 | −4 | −7 | −6 | |
| Basic net loss per share | −1.58 | −2.57 | −2.71 | −4.61 | −0.55 | |
| Diluted net loss per share | −1.58 | −2.57 | −2.71 | −4.61 | −0.55 | |
| Weighted-average shares of common stock outstanding, basic | 2 | 2 | 2 | 1 | 10 | |
| Weighted-average shares of common stock outstanding, diluted | 2 | 2 | 2 | 1 | 10 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash | 8 | 6 | 9 | — | — | |
| Prepaid expenses and other | 166,294 | 421,954 | 603,828 | 556,094 | 479,399 | |
| Total current assets | 8 | 7 | 10 | 14 | 19 | |
| Other assets | 313,921 | 313,921 | 1 | 1 | 1 | |
| Total assets | 8 | 7 | 11 | 15 | 20 | |
| Accounts payable | 258,109 | 283,615 | 240,832 | 287,360 | 362,470 | |
| Accrued expenses and other current liabilities | 709,916 | 610,648 | 568,753 | 785,796 | 1 | |
| Total current liabilities | 968,025 | 894,263 | 809,585 | 1 | 1 | |
| Total liabilities | 968,025 | 894,263 | 809,585 | 1 | 1 | |
| Commitments and contingencies (Note 11) | — | — | — | — | — | |
| Common stock, $0.001 par value; 10,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 2,293,757 and 1,544,840 shares issued as of December 31, 2025 and December 31, 2024, respectively; 2,291,056 and 1,542,139 shares outstanding as of December 31, 2025 and December 31, 2024, respectively | 2,294 | 1,545 | 1,544 | 1,520 | 13,465 | |
| Additional paid in capital | 212 | 208 | 208 | 208 | 206 | |
| Accumulated deficit | −200 | −197 | −193 | −189 | −183 | |
| Accumulated other comprehensive income | 253,734 | 253,734 | 253,734 | 253,734 | 253,734 | |
| Treasury stock | −5 | −5 | −5 | −5 | — | |
| Total stockholders' equity | 7 | 6 | 10 | 14 | 18 | |
| Total liabilities and stockholders' equity | 8 | 7 | 11 | 15 | 20 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Share-based expense | 64,787 | 171,814 | 283,085 | 511,480 | 410,437 | |
| Prepaid expenses and other | 255,660 | 181,874 | −47,734 | −103,738 | 286,007 | |
| Other long-term assets | 0 | 704,431 | 48,579 | 25,000 | −281,946 | |
| Accounts payable, accrued expenses and other current liabilities | 73,762 | 84,678 | −263,571 | −347,947 | 457,132 | |
| Net cash used in operating activities | −2 | −3 | −4 | −5 | −5 | |
| Net proceeds from issuance of common stock in October 2025 underwritten public offering | 4 | 0 | — | 0 | 11 | |
| Net cash provided by financing activities | 4 | 0 | — | 0 | 11 | |
| Net change in cash | 2 | −3 | −4 | −5 | 7 | |
| Cash paid for interest | 0 | 0 | 0 | 0 | 0 | |
| Issuance of common stock from cashless exercise of purchase warrants | 0 | 1 | 0 | 2 | 6 | |
| Conversion of Series B preferred stock to common stock | 350 | 0 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Xenetic Biosciences, Inc.'s CIK number?
Xenetic Biosciences, Inc.'s SEC CIK number is 0001534525 (1534525). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Xenetic Biosciences, Inc.'s SEC filings?
All of Xenetic Biosciences, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Xenetic Biosciences, Inc. last report earnings?
Xenetic Biosciences, Inc. (XBIO) most recently filed an earnings 8-K with the SEC on May 13, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001683168-26-003766). This is Xenetic Biosciences, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Xenetic Biosciences, Inc.'s most recent earnings 8-K?
Xenetic Biosciences, Inc.'s latest earnings 8-K (Item 2.02) was filed May 13, 2026 under accession 0001683168-26-003766. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Xenetic Biosciences, Inc.'s latest earnings 8-K →
Look up any company's CIK number →